Eli Lilly and Company (LLY)

Index:

S&P 100

$ 755.00
   
  • Change Today:
    $6.99
  • 52 Week High: $960.02
  • 52 Week Low: $570.21
  • Currency: US Dollars
  • Shares Issued: 949.78m
  • Volume: 5,685,356
  • Market Cap: $717,085m
  • RiskGrade: 179
  • Beta: 0.93

Regeneron Pharmaceuticals Covid-19 antibodies 100% effective in blocking infections

By Alexander Bueso

Date: Tuesday 26 Jan 2021

LONDON (ShareCast) - (Sharecast News) - Regeneron Pharmaceuticals antibody cocktail severely curtails Covid-19 symptoms and infections, the results of a late-stage trial showed.

The trial involving 400 patients with at least one household member sick from Covid-19 showed that the two-antibody cocktail, known as REGEN-COV, completely cut symptomatic infections of the novel coronavirus.

Overall rates of infections meanwhile were reduced by approximately half.

A rival treatment from Eli Lilly, bamlanivimab, had shown a similar efficacy the week before, reducing Covid-19 infections among nursing home resident in a trial by 80%.

As of 1650 GMT, Regeneron shares had slipped 1.11% to $542.14.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

LLY Market Data

Currency US Dollars
Share Price $ 755.00
Change Today $ 6.99
% Change 0.93 %
52 Week High $960.02
52 Week Low $570.21
Volume 5,685,356
Shares Issued 949.78m
Market Cap $717,085m
Beta 0.93
RiskGrade 179

What The Brokers Say

Strong Buy 9
Buy 12
Neutral 6
Sell 0
Strong Sell 0
Total 27
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Trades for 25-Nov-2024

Time Volume / Share Price
16:02 2,266,531 @ $755.00
15:59 100 @ $754.26
15:59 237 @ $754.26
15:59 139 @ $754.26
15:59 100 @ $753.24

Top of Page